KDCA Expands Support for Early Diagnosis of Rare Diseases
Aiming to Shorten the Average 9.2-Year Diagnostic Period
The Korea Disease Control and Prevention Agency (KDCA) announced on March 31 that it will implement the "Rare Disease Diagnostic Support Program" to facilitate early diagnosis for suspected rare disease patients and strengthen support for their families.
Rare diseases are numerous and present with diverse symptoms, resulting in an average of 9.2 years to reach an accurate diagnosis. Delayed diagnosis can mean missing the optimal treatment window or being late in connecting with relevant systems, such as special calculation exemptions and medical expense support, making institutional support for early diagnosis critical. Last year, through this program, the KDCA supported whole genome sequencing for 810 individuals, of whom 285 were confirmed to have a rare disease, resulting in a final diagnostic rate of 35.2%.
This year, the scale of support has been expanded. The program will assist 1,150 patients, an increase of 42% compared to the previous year (810 patients). However, the agency explained that there are limitations to providing diagnostic support year-round. Taking into account the annual demand for diagnostic support at medical institutions (approximately 2,700 cases), the KDCA plans to continue expanding the scale of support in the future.
Additional testing for patients' families and support for follow-up examinations after diagnosis will also be strengthened. When a hereditary rare disease is detected, testing will be offered to family members such as parents or siblings (up to about three people), enabling proactive management of high-risk groups. The program will also support screening and confirmatory tests for suspected cases of spinal muscular atrophy (SMA), where treatment costs are high and early diagnosis is essential.
Depending on the diagnostic results, the program will be linked to national policies such as special calculation exemptions and medical expense support, thereby reducing the burden on suspected rare disease patients and their families. The KDCA plans to strengthen the support system for diagnostic testing and subsequent connections, so that patients can more quickly access necessary treatment and support.
For negative or inconclusive cases that require reanalysis, the agency will obtain patient consent and pursue multi-year reanalysis in cooperation with the National Institute of Health. The KDCA expects that this will help identify genetic variants that had previously not been detected.
Patients wishing to participate in the program can receive diagnostic support through participating medical institutions near their place of residence. Further details can be found on the homepage of the KDCA’s Rare Disease Helpline.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seungkwan Lim, Commissioner of the KDCA, stated, "We will continue to ensure that suspected rare disease patients can receive a diagnosis more quickly and be connected to the necessary treatment and support without disruption."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.